REGN: Regeneron Pharmaceuticals Inc. Stocks News on November 27, 2025

Hedge Funds Pile Into Health Stocks Leading Market in Rotation

REGN

Bloomberg

19 hours ago

Hedge Funds Pile Into Health Stocks Leading Market in Rotation

REGN

Simply Wall St.

a day ago

Regeneron Pharmaceuticals (REGN): Examining Valuation After Recent Share Price Momentum

REGN

Zacks

2 days ago

SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria

REGN

MT Newswires

2 days ago

Regeneron, Sanofi Say EU Approves Dupixent for Inflammatory Skin Disease

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

REGN

GlobeNewswire

2 days ago

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Bristol Myers Pops On A 'Surprisingly Positive' Update From Key Rival Bayer

REGN

Investor's Business Daily

2 days ago

Bristol Myers Pops On A 'Surprisingly Positive' Update From Key Rival Bayer

1 Reason Why Shares of Regeneron Pharmaceuticals Are Surging This Month

REGN

Motley Fool

3 days ago

1 Reason Why Shares of Regeneron Pharmaceuticals Are Surging This Month

REGN

MT Newswires

3 days ago

HSBC Initiates Regeneron Pharmaceuticals at Buy With $890 Price Target

Jim Cramer Says He “Should Have Been Recommending Regeneron”

REGN

Insider Monkey

3 days ago

Jim Cramer Says He “Should Have Been Recommending Regeneron”

This Medicare premium just crossed $200 a month for the first time. Here’s why.

REGN

MarketWatch

5 days ago

This Medicare premium just crossed $200 a month for the first time. Here’s why.

Are Shares of Regeneron Attractive After Recent Surge on Clinical Trial Success?

REGN

Simply Wall St.

5 days ago

Are Shares of Regeneron Attractive After Recent Surge on Clinical Trial Success?

Mettler-Toledo, Agilent, Waters Corporation, Merck, and Regeneron Shares Skyrocket, What You Need To Know

REGN

StockStory

5 days ago

Mettler-Toledo, Agilent, Waters Corporation, Merck, and Regeneron Shares Skyrocket, What You Need To Know

NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?

REGN

Zacks

6 days ago

NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?

This Month's Stock Trend Hasn't Been AI. Here's What's Been Climbing Instead

REGN

Investopedia

6 days ago

This Month's Stock Trend Hasn't Been AI. Here's What's Been Climbing Instead

Are Wall Street Analysts Bullish on Regeneron Pharmaceuticals Stock?

REGN

Barchart

6 days ago

Are Wall Street Analysts Bullish on Regeneron Pharmaceuticals Stock?

3 Nasdaq 100 Stocks We Keep Off Our Radar

REGN

StockStory

6 days ago

3 Nasdaq 100 Stocks We Keep Off Our Radar

Stocks to Watch Thursday Recap: Walmart, Nvidia, Cracker Barrel, Regeneron

REGN

The Wall Street Journal

6 days ago

Stocks to Watch Thursday Recap: Walmart, Nvidia, Cracker Barrel, Regeneron

REGN

Zacks

7 days ago

REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD

Regeneron’s Eylea franchise boosted by pair of FDA approvals

REGN

Pharmaceutical Technology

7 days ago

Regeneron’s Eylea franchise boosted by pair of FDA approvals

REGN

MT Newswires

7 days ago

Raymond James Adjusts PT on Regeneron Pharmaceuticals to $800 From $723, Keeps Outperform Rating

REGN

MT Newswires

7 days ago

Wells Fargo Adjusts PT on Regeneron Pharmaceuticals to $700 From $615, Maintains Equalweight Rating

REGN

MT Newswires

7 days ago

Regeneron Gets FDA Approval for Eylea to Treat Macular Edema

EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

REGN

GlobeNewswire

7 days ago

EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

REGN

MT Newswires

8 days ago

Regeneron Pharmaceuticals Gets European Commission's Approval for Expanded Indication for Libtayo

Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation

REGN

GlobeNewswire

8 days ago

Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation

Stock Market Today: Dow Skids, AI Play Dives As Peter Thiel Exits; Netflix Divvies Up Its Shares (Live Coverage)

REGN

Investor's Business Daily

9 days ago

Stock Market Today: Dow Skids, AI Play Dives As Peter Thiel Exits; Netflix Divvies Up Its Shares (Live Coverage)

1 S&P 500 Stock with Exciting Potential and 2 We Question

REGN

StockStory

10 days ago

1 S&P 500 Stock with Exciting Potential and 2 We Question

Bristol Myers Slouches 4% After Experts Say Its Heart Drug Will Fail

REGN

Investor's Business Daily

12 days ago

Bristol Myers Slouches 4% After Experts Say Its Heart Drug Will Fail

Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls

REGN

The Fly

14 days ago

Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls

Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

REGN

GlobeNewswire

14 days ago

Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

REGN

MT Newswires

14 days ago

Scotiabank Initiates Regeneron Pharmaceuticals at Sector Perform With $650 Price Target

Here Are the Top Growth Healthcare Stocks Every New Investor Should Know

REGN

Motley Fool

14 days ago

Here Are the Top Growth Healthcare Stocks Every New Investor Should Know

REGN

Morningstar Research

14 days ago

Analyst Report: Regeneron Pharmaceuticals, Inc.

REGN

Simply Wall St.

16 days ago

Regeneron (REGN): Revisiting Valuation After Recent 16% Share Price Rally

Merck’s Heart Pill Slashes Cholesterol Levels in Test Patients

REGN

Barrons.com

16 days ago

Merck’s Heart Pill Slashes Cholesterol Levels in Test Patients

REGN

MT Newswires

17 days ago

European Equities Close Sharply Higher in Monday Trading on Hopes for End to US Government Shutdown

REGN

MT Newswires

17 days ago

Alvotech Wins UK Court Ruling Allowing Production of Biosimilar to Eylea

REGN

Clinical Trials Arena

17 days ago

Dupixent set for ninth US approval after Phase III AFRS success

REGN

StockStory

17 days ago

Winners And Losers Of Q3: Regeneron (NASDAQ:REGN) Vs The Rest Of The Immuno-Oncology Stocks

UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)

REGN

GlobeNewswire

17 days ago

UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)

REGN

Simply Wall St.

18 days ago

How Positive Phase 2 Results for Novel Antibodies at Regeneron Pharmaceuticals (REGN) Has Changed Its Investment Story

Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%

REGN

Investor's Business Daily

18 days ago

Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

REGN

GlobeNewswire

19 days ago

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

REGN

Morningstar Research

19 days ago

Analyst Report: Intellia Therapeutics, Inc.

REGN

MT Newswires

20 days ago

UBS Adjusts Price Target on Regeneron Pharmaceuticals to $660 From $595, Maintains Neutral Rating

Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble

REGN

Zacks

20 days ago

Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble

REGN

MT Newswires

20 days ago

Regeneron, Sanofi Say Dupixent for Allergic Fungal Rhinosinusitis Met Primary Endpoint in Phase 3 Study

Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review

REGN

GlobeNewswire

20 days ago

Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review

Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

REGN

GlobeNewswire

20 days ago

Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates

REGN

GlobeNewswire

20 days ago

Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates

Life Sciences, TechBio, and Investment Leaders at Demy-Colton’s BioFuture™ 2025 Suggest Health and Biotech Sectors Show Signs of New Life

REGN

Business Wire

21 days ago

Life Sciences, TechBio, and Investment Leaders at Demy-Colton’s BioFuture™ 2025 Suggest Health and Biotech Sectors Show Signs of New Life

Assessing Regeneron After New Drug Pipeline Expansions and Double-Digit Share Price Decline

REGN

Simply Wall St.

21 days ago

Assessing Regeneron After New Drug Pipeline Expansions and Double-Digit Share Price Decline

Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y

REGN

Zacks

22 days ago

Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y

Michael Burry Is Super-Bearish On Palantir — With 5 Million Puts

REGN

Benzinga

22 days ago

Michael Burry Is Super-Bearish On Palantir — With 5 Million Puts

5 Revealing Analyst Questions From Regeneron’s Q3 Earnings Call

REGN

StockStory

23 days ago

5 Revealing Analyst Questions From Regeneron’s Q3 Earnings Call

Regeneron Announces Investor Conference Presentations

REGN

GlobeNewswire

23 days ago

Regeneron Announces Investor Conference Presentations

2 Beaten-Down Stocks That Could Be About to Rally

REGN

Motley Fool

24 days ago

2 Beaten-Down Stocks That Could Be About to Rally

Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%

REGN

Motley Fool

25 days ago

Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%

REGN

MT Newswires

a month ago

Regeneron Pharmaceuticals Insider Sold Shares Worth $4,252,745, According to a Recent SEC Filing

Is OPKO’s Regeneron Deal and Asset Sale Shifting the Investment Case for OPKO Health (OPK)?

REGN

Simply Wall St.

a month ago

Is OPKO’s Regeneron Deal and Asset Sale Shifting the Investment Case for OPKO Health (OPK)?

REGN

MT Newswires

a month ago

Rothschild & Co Redburn Adjusts Price Target on Regeneron Pharmaceuticals to $910 From $900

‘Sometimes the only winning move is not to play,’ says Michael Burry in bubble warning

REGN

MarketWatch

a month ago

‘Sometimes the only winning move is not to play,’ says Michael Burry in bubble warning

AstraZeneca’s gMG drug fails to fend off rivals despite Phase III win

REGN

Clinical Trials Arena

a month ago

AstraZeneca’s gMG drug fails to fend off rivals despite Phase III win

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

REGN

GlobeNewswire

a month ago

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development and Maximize Global Platform Potential

REGN

PR Newswire

a month ago

JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development and Maximize Global Platform Potential

Opko Health Inc.’s (OPK) ModeX Therapeutics Announces License and Collaboration Agreement With Regeneron Pharmaceuticals

REGN

Insider Monkey

a month ago

Opko Health Inc.’s (OPK) ModeX Therapeutics Announces License and Collaboration Agreement With Regeneron Pharmaceuticals

REGN

Morningstar Research

a month ago

Analyst Report: Intellia Therapeutics, Inc.

REGN

Simply Wall St.

a month ago

Regeneron (REGN) Margin Compression Reinforces Cautious Community Narratives Heading Into Earnings Season

What Catalysts Are Driving the Changing Narrative for Regeneron?

REGN

Simply Wall St.

a month ago

What Catalysts Are Driving the Changing Narrative for Regeneron?

OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results

REGN

GlobeNewswire

a month ago

OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results

REGN

Morningstar Research

a month ago

Analyst Report: Regeneron Pharmaceuticals, Inc.

Regeneron Adds Fuel to Hot Healthcare Trade. Which Stocks Could Follow it Higher?

REGN

Barrons.com

a month ago

Regeneron Adds Fuel to Hot Healthcare Trade. Which Stocks Could Follow it Higher?

REGN

MT Newswires

a month ago

OPKO's ModeX, Regeneron Collaborate to Develop Antibodies for Therapeutic Indications

FDA rejects Regeneron’s pre-filled Eylea HD syringes amid filling facility woes

REGN

Pharmaceutical Technology

a month ago

FDA rejects Regeneron’s pre-filled Eylea HD syringes amid filling facility woes

REGN

MT Newswires

a month ago

RBC Raises Price Target on Regeneron Pharmaceuticals to $708 From $704, Keeps Sector Perform Rating

OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications

REGN

GlobeNewswire

a month ago

OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications

REGN

MT Newswires

a month ago

BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $725 From $640, Maintains Outperform Rating

Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts

REGN

Investor's Business Daily

a month ago

Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts

Intellia Therapeutics (NTLA) Is Down 45.2% After Pausing Key Nex-z Trials Over Safety Issue – Has The Bull Case Changed?

REGN

Simply Wall St.

a month ago

Intellia Therapeutics (NTLA) Is Down 45.2% After Pausing Key Nex-z Trials Over Safety Issue – Has The Bull Case Changed?

REGN

MT Newswires

a month ago

US Equity Indexes Break Records as Fed Set to Cut While Gains Accrue From Earnings, Corporate Actions

REGN

Motley Fool

a month ago

Regeneron (REGN) Q3 2025 Earnings Call Transcript

REGN

MT Newswires

a month ago

US Equity Markets End Higher Amid Expectations of Another Fed Rate Cut

REGN

MT Newswires

a month ago

Sector Update: Health Care Stocks Fall Late Afternoon

REGN

MT Newswires

a month ago

JPMorgan Raises Price Target on Regeneron Pharmaceuticals to $850 From $800

REGN

Zacks

a month ago

REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

REGN

GlobeNewswire

a month ago

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

OncoNano Medicine Presents First-in-Human Data Demonstrating Safety and Early Signs of Clinical Activity of ONM-501, a Dual-Acting STING Agonist, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

REGN

Business Wire

a month ago

OncoNano Medicine Presents First-in-Human Data Demonstrating Safety and Early Signs of Clinical Activity of ONM-501, a Dual-Acting STING Agonist, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

A Look at Regeneron Pharmaceuticals’s Valuation Following Key European Regulatory Win for Libtayo

REGN

Simply Wall St.

a month ago

A Look at Regeneron Pharmaceuticals’s Valuation Following Key European Regulatory Win for Libtayo

REGN

StockStory

a month ago

Regeneron Earnings: What To Look For From REGN

REGN

Insider Monkey

a month ago

European Medicines Agency Adopts a Positive Opinion on Regeneron’s (REGN) Libtayo

REGN

Morningstar Research

a month ago

Analyst Report: Sanofi

Sanofi Jumps As Dupixent Nears $5 Billion In Sales; Trump Drug Talks Continue

REGN

Investor's Business Daily

a month ago

Sanofi Jumps As Dupixent Nears $5 Billion In Sales; Trump Drug Talks Continue

Fed Rate Move, Apple Earnings, Trump-Xi Meeting: What to Watch Next Week

REGN

The Wall Street Journal

a month ago

Fed Rate Move, Apple Earnings, Trump-Xi Meeting: What to Watch Next Week

REGN

Insider Monkey

a month ago

Long Leaf Partners Fund’s Comment on Regeneron (REGN)

REGN

Zacks

a month ago

REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?

REGN

Zacks

a month ago

Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings, Beyond Revenue and EPS

REGN

Zacks

a month ago

Earnings Preview: Regeneron (REGN) Q3 Earnings Expected to Decline

The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly.

REGN

Investor's Business Daily

a month ago

The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly.

REGN

Simply Wall St.

a month ago

Is FDA and EMA Progress for Libtayo Transforming the Investment Story for Regeneron (REGN)?

REGN

MT Newswires

a month ago

Latest Regeneron Pharmaceuticals Inc. (REGN) News on November 27, 2025

Share on Social Networks: